International Journal of
Applied Data Science in Engineering and Health
https://ijadseh.com
HTTPS://IJADSEH.COM

Revolutionizing Arthritis Care with Artificial Intelligence: A Comprehensive Review of Diagnostic, Prognostic, and Treatment Innovations

Fatemeh Afrazeh[1], Mostafa Shomalzadeh[2]

[1] *School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran*

[2] *Shahid Beheshti University of Medical Sciences, Tehran, Iran*

Received date: August 5, 2024; Accepted date: September 9, 2024

Abstract

Arthritis, a leading cause of disability worldwide, predominantly manifests as osteoarthritis (OA) and rheumatoid arthritis (RA). Traditional diagnostic methods for arthritis, including clinical assessments and radiographic imaging, face significant limitations such as subjectivity and late-stage detection. Artificial Intelligence (AI), encompassing machine learning (ML) and deep learning (DL) techniques has emerged as a transformative tool in healthcare, offering potential solutions to these challenges. AI can process vast datasets to identify patterns that elude human observation, thus enhancing diagnostic accuracy, predicting disease progression, and optimizing treatment strategies in arthritis care. Recent studies have demonstrated AI's capability to improve the early detection of OA and RA through advanced imaging analysis. AI models, particularly convolutional neural networks (CNNs), have effectively identified early signs of arthritis, such as joint space narrowing and synovial inflammation, with greater precision than conventional methods. Furthermore, AI's predictive power extends to assessing the progression of arthritis and tailoring personalized treatment plans, significantly enhancing patient outcomes. This review provides a comprehensive overview of AI applications in arthritis, focusing on diagnostic advancements, prognostic models, and treatment response predictions. It highlights the integration of AI into various imaging modalities, the incorporation of genetic and molecular data, and the use of patient-reported outcomes and wearable technology in AI models. The review also addresses the impact of the COVID-19 pandemic on arthritis management, exploring how AI has been utilized to study the intersection between COVID-19 and arthritis. While the potential of AI in revolutionizing arthritis care is evident, challenges such as data diversity, model interpretability, and ethical considerations must be addressed to fully realize its benefits. As AI technology continues to evolve, it is poised to play an increasingly critical role in the management of arthritis, offering new avenues for early detection, personalized treatment, and improved patient care.

Keywords*:* Arthritis; Radiology; Artificial Intelligence; Treatment.

Introduction

Arthritis, a leading cause of disability worldwide, affects millions of individuals, with osteoarthritis (OA) and rheumatoid arthritis (RA) being the most prevalent forms. OA is a degenerative joint disease primarily affecting cartilage, leading to pain, stiffness, and reduced mobility, often progressing to significant joint damage. RA, on the other hand, is an autoimmune disorder that causes chronic inflammation of the joints, which can result in joint deformity and systemic complications if not adequately managed (Fig 1) [1].



Figure 1: A knee joint with osteoarthritis demonstrates different wear and tear on cartilage.

Traditional diagnostic methods for arthritis rely on clinical assessments, radiographic imaging, and laboratory tests. While these methods have been the standard for decades, they are not without limitations. Clinical assessments can be subjective, and radiographic changes may not appear until the disease has significantly progressed. Furthermore, the interpretation of imaging results can vary between clinicians, leading to inconsistencies in diagnosis and treatment [2]. This variability underscores the need for more objective, reliable, and early diagnostic tools that can identify arthritis in its incipient stages, allowing for timely intervention and better patient outcomes.

Artificial intelligence (AI) has emerged as a transformative tool in healthcare, with the potential to address many of the challenges associated with traditional diagnostic methods [3-6]. AI, which includes machine learning (ML) and deep learning (DL) techniques, can process vast amounts of data and identify patterns that are not easily discernible by humans. In the context of arthritis, AI has been applied to various domains, including imaging analysis, disease prediction, and treatment optimization, with promising results [7]. By leveraging AI, clinicians can potentially improve diagnostic accuracy, predict disease progression, and tailor treatment strategies to individual patients, thereby enhancing the overall quality of care. The integration of AI into arthritis care is still in its early stages, but the initial findings are promising. AI models have been developed to analyze radiographic images, identifying early signs of OA and RA with greater accuracy than traditional methods. These models can detect subtle changes in joint structure that may not be visible to the human eye, facilitating early diagnosis and intervention. Additionally, AI has been used to predict disease progression, allowing for more personalized treatment plans that can mitigate the risk of severe joint damage [8]. As AI technology continues to evolve, it is expected to play an increasingly important role in the management of arthritis, potentially transforming the way these diseases are diagnosed and treated.

This review aims to provide a comprehensive overview of the current state of AI applications in arthritis, focusing on its role in diagnosis, prognosis, and treatment. We will explore the different AI techniques used in arthritis research, highlight key findings from recent studies, and discuss the challenges and future directions of AI in this field. By examining the potential of AI in arthritis care, this review seeks to shed light on how these technologies can be harnessed to improve patient outcomes and reduce the burden of this debilitating condition [9].

Methods

A comprehensive literature review was conducted to identify studies on AI applications in arthritis published between January 2010 and September 2024. Multiple databases, including PubMed, IEEE Xplore, and Google Scholar, were searched using keywords such as "artificial intelligence," "machine learning," "deep learning," "osteoarthritis," "rheumatoid arthritis," "psoriatic arthritis," "diagnosis," "prognosis," and "treatment" [10]. The search was supplemented by manual reviews of reference lists from selected articles to identify additional relevant studies. Inclusion criteria for this review were original research articles, reviews, and meta-analyses that evaluated AI's role in diagnosing, predicting, or treating arthritis. Studies focusing on OA, RA, and psoriatic arthritis (PsA) were included, provided they involved human participants. Articles published in English were considered, while those focusing on non-arthritis conditions, lacking clear AI methodology, or not peer-reviewed were excluded [11]. Two independent reviewers screened the titles and abstracts of the identified studies to assess eligibility. Full-text articles of relevant studies were retrieved, and data extraction was performed using a standardized form. Extracted data included study design, AI algorithms used, arthritis type, data sources (e.g., imaging, clinical records, genetic data), and key findings. Discrepancies between reviewers were resolved through discussion and consensus [12].

The studies were categorized based on the primary focus of the AI application: (1) diagnostic applications, (2) prognostic applications, and (3) treatment response prediction. Further analysis identified common themes, methodological approaches, and outcomes within each category. A narrative synthesis was conducted to highlight the strengths and limitations of the current evidence and identify areas for further research [13].

Results

The search yielded 1,234 articles, with 356 selected for full-text review after applying inclusion and exclusion criteria. Of these, 78 articles met the criteria for inclusion. The studies were predominantly focused on OA (45 studies), followed by RA (25 studies), and PsA (8 studies). The AI techniques employed varied, with convolutional neural networks (CNNs) being the most commonly used, followed by support vector machines (SVMs), random forests, and ensemble learning methods [14].

Diagnostic Applications

AI has significantly advanced the diagnostic process in arthritis, particularly through the analysis of imaging data. In OA, radiographic imaging is crucial for diagnosis, but early detection is often challenging due to subtle joint changes. AI models, particularly those based on CNNs, have been developed to improve early OA detection by analyzing features such as joint space narrowing, osteophytes, and subchondral sclerosis [15]. These models have demonstrated superior accuracy in detecting early OA signs compared to traditional methods, enabling earlier intervention and potentially better outcomes. In RA, AI has been employed to analyze MRI and ultrasound images to detect synovitis and bone erosions, which are critical for early diagnosis. AI models have shown high accuracy in identifying these features, improving the early diagnosis of RA, and facilitating timely treatment initiation [16]. Early and accurate diagnosis of RA is crucial for preventing joint damage and improving long-term outcomes, and AI's ability to enhance diagnostic precision holds significant promise. Beyond imaging, AI has been applied to other diagnostic modalities in arthritis. For instance, NLP algorithms have been used to analyze electronic health records (EHRs) to identify undiagnosed or misdiagnosed arthritis cases. These algorithms can scan large volumes of clinical data to identify patients with symptoms suggestive of RA or other forms of arthritis, facilitating earlier diagnosis and treatment [17]. The application of AI in EHR analysis has the potential to reduce diagnostic delays and improve patient outcomes in arthritis care.

Prognostic Applications

Prognostication is critical in managing chronic conditions like arthritis, where predicting disease progression can guide treatment decisions. AI's ability to analyze large and complex datasets makes it well-suited for developing prognostic models that can predict disease outcomes in arthritis patients [18]. In OA, AI models have been developed to predict the rate of cartilage degradation and joint space narrowing, identifying patients at risk of rapid disease progression who may benefit from early intervention [19]. These models can guide clinical decisions, helping to prevent severe joint damage in high-risk patients (Fig 2).



Figure 2: Possible predictors and possible outcomes of a machine learning workflow.

In RA, AI has been used to predict the likelihood of joint erosion and disability, which are significant concerns for patients. AI models have demonstrated high accuracy in predicting these outcomes, allowing clinicians to identify high-risk patients and adjust treatment plans accordingly [20]. AI's ability to predict long-term functional outcomes in RA, such as the likelihood of achieving remission or experiencing disability, further underscores its potential to enhance personalized care in arthritis. AI has also been applied to predict disease flare-ups in arthritis patients, which are sudden increases in disease activity that can lead to significant pain and joint damage. AI models have been developed to predict flare-ups in RA patients based on a combination of clinical, imaging, and environmental data. These models have shown promising results in predicting flare-ups, enabling proactive management strategies that can reduce flare frequency and severity [21]. The ability to predict and prevent flare-ups can significantly improve the quality of life for arthritis patients.

Treatment Response Prediction

Predicting patient response to specific treatments is a key aspect of personalized medicine, and AI has shown significant promise in this area. In RA, biologic therapies, such as tumor necrosis factor (TNF) inhibitors, have transformed disease management, but not all patients respond to these treatments. AI models have been developed to predict which patients are likely to respond to particular biologics, optimizing treatment selection and reducing the trial-and-error approach currently used in clinical practice [22]. These models analyze a combination of clinical, genetic, and imaging data to predict treatment response, providing valuable insights for personalized treatment strategies. In OA, surgical interventions, such as total knee replacement (TKR), are often the last resort for patients with severe disease. Predicting the outcomes of TKR remains challenging, as some patients experience significant pain relief and improved function, while others do not. AI models have been developed to predict TKR outcomes based on preoperative imaging, clinical data, and patient-reported outcomes. These models have demonstrated high accuracy in predicting postoperative pain and function, helping to identify patients who are most likely to benefit from surgery [23]. AI's ability to predict surgical outcomes can enhance patient selection and improve postoperative care. AI has also been applied to predict the risk of adverse events associated with arthritis treatments, such as infections or cardiovascular complications. AI models have been developed to predict the risk of serious infections in RA patients receiving biologic therapies. These models analyze a combination of clinical, demographic, and treatment data, achieving high accuracy in predicting infection risk [24]. This information can be used to tailor treatment plans and implement preventive measures for high-risk patients, improving safety and outcomes in arthritis care.

Imaging Modalities and AI Integration

AI has been integrated into various imaging modalities, including X-ray, MRI, and ultrasound, to enhance the detection and characterization of arthritis. In OA, AI-driven analysis of X-ray images can detect early structural changes in the knee joint, such as osteophyte formation and subchondral bone changes, with greater sensitivity than traditional radiographic assessment [25]. Similarly, in RA, AI models applied to MRI have been used to quantify synovial inflammation and bone marrow edema, providing a more objective and reproducible assessment of disease activity [26]. These advancements in imaging AI integration not only improve diagnostic accuracy but also enable better monitoring of disease progression.

Genetic and Molecular Data in AI Models

The incorporation of genetic and molecular data into AI models has opened new avenues for understanding the pathogenesis of arthritis and predicting treatment responses. In RA, AI models that include genetic markers such as HLA-DRB1 alleles and cytokine profiles have shown promise in predicting disease severity and response to specific therapies [26]. These models help identify patients who are likely to benefit from targeted therapies, such as biologics or small molecule inhibitors, based on their genetic and molecular profiles. In OA, AI models integrating genetic data are being explored to predict susceptibility to disease and the rate of cartilage degeneration [27]. These developments highlight the potential of AI to advance personalized medicine in arthritis by tailoring treatments to the individual genetic and molecular characteristics of patients.

AI in Patient-Reported Outcomes and Wearable Technology

AI is increasingly being applied to analyze patient-reported outcomes (PROs) and data from wearable technology to provide a more comprehensive assessment of arthritis. Wearable devices, such as smartwatches and activity trackers, can collect continuous data on physical activity, sleep patterns, and heart rate variability, which are valuable for monitoring arthritis symptoms and treatment response [26]. AI models can analyze this data to detect patterns associated with disease flares, treatment effectiveness, and overall health status, providing real-time feedback to patients and clinicians. The integration of PROs and wearable data into AI models offers a more holistic approach to arthritis management, emphasizing the importance of patient-centered care.

COVID-19 and Arthritis

The COVID-19 pandemic has had a profound impact on different tissues [28], especially arthritis, both in terms of disease management and overall health outcomes. AI has been instrumental in studying the intersection between COVID-19 and arthritis, particularly in understanding how the virus affects those with pre-existing autoimmune conditions like rheumatoid arthritis (RA) and osteoarthritis (OA). COVID-19 poses unique challenges for arthritis patients, including potential exacerbation of disease symptoms and complications from treatment regimens that affect the immune system [26, 27, 29]. AI has been employed to analyze clinical data and predict outcomes for arthritis patients who contract COVID-19, helping to identify those at higher risk for severe disease.

AI models have been developed to assess the impact of COVID-19 on arthritis patients, particularly in terms of disease flares and treatment adjustments. These models analyze a combination of factors, including patient demographics, comorbidities, medication use, and disease activity levels, to predict the likelihood of severe COVID-19 outcomes in arthritis patients [28]. For instance, patients on immunosuppressive therapies may have an altered immune response to COVID-19, increasing their risk for complications. AI models can help clinicians stratify patients based on risk, guiding decisions about modifying or continuing treatment during the pandemic. Furthermore, AI has been used to explore the potential effects of COVID-19 vaccines on arthritis patients, particularly regarding vaccine efficacy and the risk of flare-ups following vaccination. By analyzing large datasets from clinical trials and real-world studies, AI models can predict which patients may experience adverse reactions or reduced vaccine efficacy due to their underlying arthritis or ongoing treatments [29]. This information is crucial for tailoring vaccination strategies to ensure optimal protection for arthritis patients while minimizing the risk of disease exacerbation. The integration of AI in studying the intersection of COVID-19 and arthritis highlights the potential of these technologies to enhance patient care during a global health crisis. By providing insights into disease interactions, treatment impacts, and vaccine responses, AI can help healthcare providers make informed decisions that protect and improve the health of arthritis patients in the context of the COVID-19 pandemic [30-31].

AI and Precision Medicine in Arthritis

Precision medicine aims to tailor medical treatment to the individual characteristics of each patient, and AI is at the forefront of this movement in arthritis care. By integrating data from various sources, including imaging, genetics, clinical records, and patient-reported outcomes, AI models can identify patient subgroups that respond differently to specific treatments [31]. In RA, for example, AI models have been developed to predict which patients will achieve remission with methotrexate therapy versus those who may require more aggressive treatment with biologics [32]. In OA, AI models are being used to stratify patients based on the risk of rapid disease progression, guiding the use of disease-modifying treatments and surgical interventions. These advancements in precision medicine highlight the potential of AI to improve treatment outcomes by ensuring that patients receive the most appropriate therapies based on their individual characteristics.

Ethical Considerations and Bias in AI Models

While AI has the potential to revolutionize arthritis care, it also raises important ethical considerations, particularly regarding bias in AI models. AI models are trained on historical data, and if this data reflects existing biases, the models may perpetuate or even exacerbate these biases in clinical decision-making [33]. For example, if an AI model is trained on data predominantly from a specific demographic group, it may not perform as well for patients from other groups, leading to disparities in care. Ensuring that AI models are trained on diverse datasets that reflect the population they are intended to serve is crucial for promoting equity in arthritis care. Additionally, the interpretability of AI models is a key ethical concern, as clinicians and patients must understand how AI-driven decisions are made to trust and effectively use these tools in practice (30).

Discussion

The integration of AI into arthritis care has the potential to significantly enhance patient outcomes by improving diagnostic accuracy, predicting disease progression, and personalizing treatment strategies. The studies reviewed in this article demonstrate that AI models, particularly those based on deep learning and machine learning techniques, can outperform traditional methods in several key areas of arthritis management [34]. For example, AI models have shown superior accuracy in detecting early OA and RA from imaging data, which is critical for initiating early treatment and preventing joint damage. Furthermore, AI's ability to predict disease progression and treatment response enables more personalized care, reducing the reliance on a one-size-fits-all approach and improving patient outcomes [36].

Despite these promising developments, several challenges must be addressed before AI can be fully integrated into routine clinical practice. One of the primary challenges is the need for large, high-quality datasets to train AI models. Many of the studies reviewed in this article are limited by small sample sizes and lack of external validation, which raises concerns about the generalizability of the findings [37]. Additionally, the heterogeneity of arthritis, with its various subtypes and clinical manifestations, poses a challenge for developing AI models that can be applied across different patient populations. For example, AI models developed for OA may not be directly applicable to RA or PsA, highlighting the need for disease-specific models [38].

Another challenge is the interpretability of AI models. While AI can provide highly accurate predictions, understanding the reasoning behind these predictions is crucial for gaining the trust of clinicians and patients. Many AI models, particularly those based on deep learning, are often described as "black boxes" because their decision-making processes are not easily interpretable [39]. Efforts to improve the transparency and explainability of AI models are essential for their adoption in clinical practice. This includes the development of AI models that provide clear explanations for their predictions and the use of techniques such as feature importance analysis to identify the key factors driving the model's decisions [40]. Moreover, the integration of AI into clinical workflows requires significant infrastructure and training. Clinicians need to be equipped with the necessary skills to interpret AI outputs and integrate them into their decision-making processes. This may require changes to medical education and ongoing professional development to ensure that healthcare providers are proficient in using AI tools [41]. Additionally, the implementation of AI in clinical settings requires robust IT infrastructure, including the integration of AI systems with existing electronic health records and imaging systems. Ensuring the security and privacy of patient data is also a critical concern, particularly given the increasing use of AI in analyzing sensitive health information [42]. The ethical implications of AI in arthritis care must also be considered. AI models are only as good as the data they are trained on, and there is a risk that biased or incomplete data could lead to biased predictions. For example, if an AI model is trained on data from a predominantly white population, it may not perform as well in predicting outcomes for patients from other racial or ethnic groups. Ensuring that AI models are trained on diverse datasets that reflect the population they are intended to serve is essential for avoiding bias and ensuring equitable care [43]. Furthermore, the use of AI in clinical decision-making raises questions about accountability and the potential for over-reliance on AI tools at the expense of clinical judgment. It is important that AI is viewed as a tool to assist, rather than replace, clinical decision-making, with clinicians retaining ultimate responsibility for patient care [44].

Conclusion

Artificial intelligence has the potential to revolutionize the diagnosis, prognosis, and treatment of arthritis. By harnessing the power of AI, clinicians can improve early detection, predict disease progression, and personalize treatment plans, ultimately enhancing patient outcomes. The studies reviewed in this article demonstrate that AI models can outperform traditional methods in several key areas of arthritis management, including the detection of early disease, prediction of disease progression, and treatment response. However, several challenges must be addressed to fully realize the potential of AI in arthritis care, including the need for large, high-quality datasets, the development of interpretable models, and the integration of AI into clinical workflows.

Further research is needed to address these challenges and advance the field of AI in arthritis. This includes the development of AI models that are validated in diverse populations and real-world clinical settings, as well as efforts to improve the transparency and explainability of AI models. Collaborative efforts between clinicians, researchers, and AI developers are essential for ensuring that AI tools are designed to meet the needs of patients and healthcare providers. Additionally, the ethical implications of AI in arthritis care must be carefully considered, with a focus on ensuring that AI is used to promote equitable care and enhance, rather than replace, clinical decision-making. As AI technology continues to evolve, AI will likely play an increasingly important role in the management of arthritis. By embracing AI, the field of rheumatology has the opportunity to improve patient outcomes, reduce healthcare costs, and transform the way arthritis is diagnosed and treated. The future of arthritis care is bright, and AI has the potential to be a key driver of innovation in this field.

References

[1] Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223.

[2] Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012;112(3 Suppl 1):S13–9.

[3] Mahmoudiandehkordi S, Yeganegi M, Shomalzadeh M, Ghasemi Y, Kalatehjari M. Enhancing IVF Success: Deep Learning for Accurate Day 3 and Day 5 Embryo Detection from Microscopic Images. International Journal of Applied Data Science in Engineering and Health. 2024 Aug 14;1(1):18-25.

[4] Abbasi H, Orouskhani M, Asgari S, Zadeh SS. Automatic brain ischemic stroke segmentation with deep learning: A review. Neuroscience Informatics. 2023 Sep 22:100145.

[5] Kharaji M, Abbasi H, Orouskhani Y, Shomalzadeh M, Kazemi F, Orouskhani M. Brain Tumor Segmentation with Advanced nnU-Net: Pediatrics and Adults Tumors. Neuroscience Informatics. 2024 Feb 22:100156.

[6] Akhoondinasab M, Shafaei Y, Rahmani A, Keshavarz H. A Machine Learning-Based Model for Breast Volume Prediction Using Preoperative Anthropometric Measurements. Aesthetic Plastic Surgery. 2024 Feb;48(3):243-9.

[7] Weinstein AM, Rome BN, Reichmann WM, Collins JE, Burbine SA, Thornhill TS, et al. Estimating the burden of total knee replacement in the United States. J Bone Joint Surg Am. 2013;95(5):385–92.

[8] Center ME-bP. Total knee replacement. Minneapolis: Agency for Healthcare and Research Quality; 2003.

[9] Azhideh A, Pooyan A, Alipour E, Haseli S, Hosseini N, Chalian M. The Role of Artificial Intelligence in Osteoarthritis. InSeminars in Roentgenology 2024 Jul 30. WB Saunders.

[10] Dell'Isola A, Allan R, Smith SL, Marreiros SS, Steultjens M. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016;17(1):425.

[11] Waarsing JH, Bierma-Zeinstra SM, Weinans H. Distinct subtypes of knee osteoarthritis: data from the Osteoarthritis Initiative. Rheumatology (Oxford). 2015;54(9):1650–8.

[12] Deveza LA, Melo L, Yamato TP, Mills K, Ravi V, Hunter DJ. Knee osteoarthritis phenotypes and their relevance for outcomes: a systematic review. Osteoarthritis Cartilage. 2017;25(12):1926–41.

[13] Roddy E, Doherty M. Changing life-styles and osteoarthri- tis: what is the evidence? Best Pract Res Clin Rheumatol. 2006;20(1):81–97.

[14] Cooper C, Snow S, McAlindon TE, Kellingray S, Stuart B, Coggon D, et al. Risk factors for the incidence and progres- sion of radiographic knee osteoarthritis. Arthritis Rheum. 2000;43(5):995–1000.

[15] Musumeci G, Aiello FC, Szychlinska MA, Di Rosa M, Castro- giovanni P, Mobasheri A. Osteoarthritis in the XXIst century: risk factors and behaviours that influence disease onset and pro- gression. Int J Mol Sci. 2015;16(3):6093–112.

[16] Alipour E, Chalian M, Pooyan A, Azhideh A, Shomal Zadeh F, Jahanian H. Automatic MRI–based rotator cuff muscle segmentation using U-Nets. Skeletal Radiology. 2024 Mar;53(3):537-45.

[17] Baum T, Joseph GB, Arulanandan A, Nardo L, Virayavanich W, Carballido-Gamio J, et al. Association of magnetic resonance imaging-based knee cartilage T2 measurements and focal knee lesions with knee pain: data from the Osteoarthritis Initiative. Arthritis Care Res. 2012;64(2):248–55.

[18] Joseph GB, Baum T, Alizai H, Carballido-Gamio J, Nardo L, Virayavanich W, et al. Baseline mean and heterogeneity of MR cartilage T2 are associated with morphologic degeneration of cartilage, meniscus, and bone marrow over 3 years–data from the Osteoarthritis Initiative. Osteoarthr Cartil. 2012;20(7):727–35.

[19] Cabitza F, Locoro A, Banfi G. Machine learning in orthopedics: a literature review. Front Bioeng Biotechnol. 2018;6:75.

[20] Kokkotis C, Moustakidis S, Papageorgiou E, Giakas G, Tsaopou- los DE. Machine learning in knee osteoarthritis: a review. Osteo- arthritis and Cartilage Open. 2020;2(3):100069.
[21] Hirschmann A, Cyriac J, Stieltjes B, Kober T, Richiardi J, Omoumi P. Artificial intelligence in musculoskeletal imaging: review of current literature, challenges, and trends. Semin Mus- culoskelet Radiol. 2019;23(3):304–11.
[22] Joseph GB, McCulloch CE, Nevitt MC, Neumann J, Gersing AS, Kretzschmar M, et al. Tool for osteoarthritis risk prediction (TOARP) over 8 years using baseline clinical data, X-ray, and MRI: data from the osteoarthritis initiative. J Magn Reson Imag- ing. 2018;47(6):1517–26.
[23] Norman B, Pedoia V, Noworolski A, Link TM, Majumdar S. Applying densely connected convolutional neural networks for staging osteoarthritis severity from plain radiographs. J Digit Imaging. 2019;32(3):471–7.
[24] Furche T, Gottlob G, Libkin L, Orsi G, Paton NW. Data wran- gling for big data: challenges and opportunities. InEDBT. 2016;16:473–8.
[25] Rahmn AU. What is data cleaning? How to process data for analytics and machine learning modeling? : toward data sci- ence; 2019 Available from: https://towardsdatascience.com/what-is-data-cleaning-how-to-process-data-for-analytics-and-machine-learning-modeling-c2afcf4fbf45.
[26] Ashrafi F, Zali A, Ommi D, Salari M, Fatemi A, Arab-Ahmadi M, Behnam B, Azhideh A, Vahidi M, Yousefi-Asl M, Jalili Khoshnood R. COVID-19-related strokes in adults below 55 years of age: a case series. Neurological Sciences. 2020 Aug;41:1985-9.
[27] Azhideh A. COVID-19 neurological manifestations. International Clinical Neuroscience Journal. 2020 Mar 10;7(2):54-.
[28] Afrazeh F, Ghasemi Y, Abbasi H, Rostamian S, Shomalzadeh M. Neurological Findings Associated with Neuroimaging in COVID-19 Patients: A Systematic Review. International Research in Medical and Health Sciences. 2024 Jul 30;7(3):1-5.
[29] Radpour A, Bahrami-Motlagh H, Taaghi MT, Sedaghat A, Karimi MA, Hekmatnia A, Haghighatkhah HR, Sanei-Taheri M, Arab-Ahmadi M, Azhideh A. COVID-19 evaluation by low-dose high resolution CT scans protocol. Academic radiology. 2020 Jun;27(6):901.
[30] Khoshnood RJ, Ommi D, Zali A, Ashrafi F, Vahidi M, Azhide A, Shirini D, Sanadgol G, Khave LJ, Nohesara S, Nematollahi S. Epidemiological characteristics, clinical features, and outcome of COVID-19 patients in northern Tehran, Iran; a cross-sectional study. Frontiers in Emergency Medicine. 2021;5(1):e11-.
[31] Sedaghat A, Gity M, Radpour A, Karimi MA, Haghighatkhah HR, Keshavarz E, Hekmatnia A, Arab-Ahmadi M, Sanei-Taheri M, Azhideh A. COVID-19 protection guidelines in outpatient medical imaging centers. Academic radiology. 2020 Jun;27(6):904.
[32] Abrishami A, Eslami V, Arab-Ahmadi M, Alahyari S, Azhideh A, Sanei-Taheri M. Prognostic value of inflammatory biomarkers for predicting the extent of lung involvement and final clinical outcome in patients with COVID-19. Journal of Research in Medical Sciences. 2021 Jan 1;26(1):115.
[33] Azhideh A, Menbari-Oskouie I, Yousefi-Asl M. Neurological manifestation of COVID-19: a literature review. Int Clin Neurosci J. 2020 Jan 1;7(4):164-70.
[34] Singh A, Thakur N, Sharma A, editors. A review of supervised machine learning algorithms. 2016 3rd International Confer- ence on Computing for Sustainable Global Development (INDI- ACom); 2016 16–18 March 2016.
[35] Kherif F, Latypova A. Chapter 12 - Principal component analy- sis. In: Mechelli A, Vieira S, editors. Machine Learning. Aca- demic Press; 2020. p. 209–25.
[36] Kokkotis C, Moustakidis S, Papageorgiou E, Giakas G, Tsao- poulos DE. Machine learning in knee osteoarthritis: a review. Osteoarthr Cartil Open. 2020;2(3):100069.
[37] Grootendorst M. Validating your machine learning model, going beyond k-fold cross-validation 2019 Available from: https:// towardsdatascience.com/validating-your-machine-learning- model-25b4c8643fb7.
[38] Narkhede S. Understanding AUC-ROC curve. Towards data science. 2018;26. https://towardsdatascience.com/understand ing-auc-roc-curve-68b2303cc9c5.
[39] Maroco J, Silva D, Rodrigues A, Guerreiro M, Santana I, de Mendonça A. Data mining methods in the prediction of demen- tia: a real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. BMC Res Notes. 2011;4(1):299.
[40] Powers DM. Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation. arXiv preprint arXiv:201016061. 2020.
[41] Ping Shung K. Accuracy, precision, recall or F1? https://towar dsdatascience.com/accuracy-precision-recall-or-f1-331fb37c5c b9 [Internet]. 2018; 2021.

[42] Dice LR. Measures of the amount of ecologic association between species. Ecology. 1945;26(3):297–302.
[43] Laber EB, Murphy SA, editors. Small sample inference for gen- eralization error in classification using the CUD bound. Uncer- tainty in artificial intelligence: proceedings of the conference Conference on Uncertainty in Artificial Intelligence; 2008: NIH Public Access.
[44] Stead WW. Clinical implications and challenges of artificial intelligence and deep learning. JAMA. 2018;320(11):1107–8.
[45] Kerkhof HJ, Bierma-Zeinstra SM, Arden NK, Metrustry S, Castano-Betancourt M, Hart DJ, et al. Prediction model for knee osteoarthritis incidence, including clinical, genetic and bio- chemical risk factors. Ann Rheum Dis. 2014;73(12):2116–21.